Skip To Main Content
Healthcare Professionals Site

Prescribing Information

View Important Safety Information >

 

SIGN UP FOR EXPERT ADVICE AND COMPREHENSIVE SUPPORT

The Esbriet® Inspiration Program​™ is a free patient support program designed to help you as you start and continue on your treatment journey

As you start treatment with Esbriet® (pirfenidone), you may have questions, like what should you know about this medicine and how can Esbriet help?

When you sign up with the Esbriet® Inspiration Program™, a team of knowledgeable specialists will share tips and advice on living with idiopathic pulmonary fibrosis (IPF) and taking Esbriet, every step of the way.

After signing up, you'll have the option to meet with a Clinical Education Manager (CEM) with experience in IPF and Esbriet. CEMs offer education on living with IPF, taking Esbriet, and managing common side effects. CEMs can also help with navigating insurance coverage for Esbriet and finding available financial resources.

Which best describes you?*

How long ago were you diagnosed with IPF?*

How long ago was the person for whom you care diagnosed with IPF?*

By providing this information you agree to allow Genentech and its agents to collect the information provided and to be contacted by Genentech and its agents using this information in the future. Furthermore, you agree that Genentech and its agents may contact you as part of a marketing program by phone, email or mail, and that such electronic or other written communications may include information regarding your health from them. We may share your information with our partners and those who work with them as well as with your doctor as needed.

You are authorizing Genentech to use auto-dialers, prerecorded messages, and artificial voice messages to contact you. These calls and text messages may market or advertise Genentech products, goods, or services. You are not required to consent to being contacted by phone or text message as a condition of any purchase of goods or services. We may share your information with our partners and those who work with them as well as with your doctor as needed. Genentech will not sell, rent or otherwise distribute your name and any personally identifiable information outside of Genentech and its agents. Genentech will only use your information in accordance with the Genentech Privacy Policy, available at www.gene.com/privacy-policy.

Unsubscribe
Patient Ambassador Frank

During the first 4 months of being on Esbriet® (pirfenidone), both my wife and I met with Barbara, a CEM from Genentech*. Each meeting, we covered any issues I may be having while taking Esbriet, as well as dealing with IPF…we discussed our concerns and feelings about my diagnosis and living with IPF. She wasn't a doctor and didn't give me medical advice, but each time we came away feeling uplifted and encouraged about my journey. By our last meeting with Barbara, I felt confident that I knew what was going on and when to call my doctor if something comes up"

Frank
Esbriet Ambassador


*CEMs are Genentech employees who educate about IPF and Esbriet® (pirfenidone). They do not provide medical advice. If you have questions about your health or treatment, you are encouraged to contact your healthcare provider.

 

Thank you

Your request has been submitted.
Esbriet Patient Support

ENROLL TODAY TO START GETTING:

  • Ongoing information about IPF and treatment
  • Encouragement from others taking Esbriet
  • Free one-on-one educational sessions about your IPF treatment and financial assistance options*
  • And more

*Genentech’s educators do not provide medical advice. If you have questions about your health or treatment, you are encouraged to contact your healthcare provider.

About Esbriet

Esbriet® (pirfenidone) is a prescription medicine used to treat people with a lung disease called idiopathic pulmonary fibrosis (IPF).

It is not known if Esbriet is safe and effective in children.

Before you take Esbriet, tell your doctor if you:
  • have other medical conditions (particularly liver or kidney problems).
  • are a smoker.
  • are or plan to become pregnant or breastfeed (Esbriet has not been studied in these patients).
  • are taking any prescription or over-the-counter medicines, vitamins, or herbal supplements.
What are the possible side effects of Esbriet?

Esbriet may cause serious side effects, including:

  • liver problems. Call your doctor if you have symptoms such as yellowing of your skin or eyes, dark or brown urine, pain on the upper right side of your stomach area, bleeding or bruising more easily than normal, or increased fatigue. Your doctor will also do regular blood tests to check your liver.
  • sun sensitivity and rash. When you are outside, use sunscreen (SPF 50) and wear a hat and clothes that cover your skin to avoid getting a sunburn.
  • stomach problems. Esbriet may cause stomach problems such as nausea, vomiting, diarrhea, indigestion, heartburn, and stomach pain.

Your doctor may change your dose or discontinue Esbriet if side effects do not go away.

The most common side effects of Esbriet include upper respiratory tract infections, feeling tired, headache, dizziness, loss of appetite, sinusitis, insomnia, or weight loss.

These are not all the possible side effects of Esbriet.

What should you avoid while taking Esbriet?
  • Direct exposure to sunlight, or light from sunlamps and tanning beds.
  • Other medicines that can make your skin sensitive to sunlight.
  • Smoking, which may affect how well Esbriet works.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch or to Genentech at 1-888-835-2555.

Please see full Prescribing Information, including Patient Information, for additional important safety information.

    • Centers for Medicare & Medicaid Services. Advance notice of methodological changes for calendar year (CY) 2018 for Medicare Advantage (MA) capitation rates, Part C and Part D payment policies and 2018 call letter. https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Advance2018.pdf. Posted February 1, 2017. Accessed October 17, 2017.

      Centers for Medicare & Medicaid Services. Advance notice of methodological changes for calendar year (CY) 2018 for Medicare Advantage (MA) capitation rates, Part C and Part D payment policies and 2018 call letter. https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Advance2018.pdf. Posted February 1, 2017. Accessed October 17, 2017.